Consistently, preclinical studies have evidenced that NB cells are very sensitive to inhibitors of MDM2, such as nutlin-3a, including in p53-null NB cells with MYCN amplification, which demonstrates a p53-independent mechanism of action of these drugs, namely by targeting the MYCN pathway [53,54,55] (Figure 2). This evidence concerns the gene TP53 and neuroblastoma.